Richard L. Schilsky, MD, from University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.
Richard L. Schilsky, MD, Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.
In the world, 70% of all generic drugs are made by three manufacturers and 80% are made by five manufacturers. Schilsky points out that these manufacturers have a very thin profit margin on many drugs and have tough decisions to make when problems arise.
One reason generic drug user fees are so important to the FDA is that there is a huge backlog of applications to review. The hope is that generic drug user fees will give resources to the FDA to help reduce review times.
<<<
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More